Cadrenal Therapeutics Inc

CVKD04 Dec 2024
Healthcare
$14.9
-0.01 (-0.89%)
Lowest Today
$13.59
Highest Today
$15.1
Today’s Open
$14.9
Prev. Close
$14.01
52 Week High
$32.55
52 Week Low
$5.4
To Invest in Cadrenal Therapeutics Inc

Cadrenal Therapeutics Inc

Healthcare
CVKD04 Dec 2024
-0.01 (-0.89%)
1M
3M
6M
1Y
5Y
Low
$13.59
Day’s Range
High
$15.1
13.59
52 Week Low
$5.4
52-Week Range
52 Week High
$32.55
5.4
1 Day
-
1 Week
+1.22%
1 month return
-0.42%
3 month return
+72.41%
6 month return
+2872.39%
1 Year return
+2488.27%
3 Years return
-
5 Years return
-
10 Years return
-

Market Status

Fundamentals
Market Cap
25.2 mln
PB Ratio
7.38
PE Ratio
0
Enterprise Value
20.84 mln
Total Assets
8.52 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Organisation
Cadrenal Therapeutics Inc
Employees
4
Industry
Biotechnology
CEO
Mr. Quang X. Pham
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step